M. Shtivelband

发表

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer

M. Socinski, D. Moro-Sibilot, C. Barone, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

V. Devanarayan, K. Pittman, T. Owonikoko, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

M. Campone, A. Manikhas, L. Dirix, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel and bavituximab in nonsquamous NSCLC 1 Docetaxel Plus Bavituximab in Previously Treated , Advanced Nonsquamous Non – small-cell Lung Cancer

D. Gerber, D. Spigel, C. Belani, 2016 .

Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer.

D. Gerber, D. Spigel, C. Belani, 2016, Clinical lung cancer.

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

A. Schneeweiss, N. Harbeck, J. Cortes, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

M. Piccart, G. Hortobagyi, J. Baselga, 2013, European journal of cancer.

Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

G. Hortobagyi, J. Baselga, M. Campone, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of p90 Ribosomal S6 Kinase-mediated CCAAT/Enhancer-binding Protein β Activation and Cyclooxygenase-2 Expression by Salicylate*

Ying-hua Zhu, Kenneth K. Wu, K. Cieslik, 2005, Journal of Biological Chemistry.

Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

A. Schneeweiss, N. Harbeck, J. Cortes, 2017 .

Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

J. Baselga, H. Rugo, M. Campone, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.

J. Burke, K. Kolibaba, I. Flinn, 2021, The Lancet. Haematology.

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

A. Garg, M. Piccart, G. Hortobagyi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

P. Neven, M. Piccart, G. Hortobagyi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Everolimus in hormone receptor-positive advanced breast cancer: targeting receptor-based mechanisms of resistance.

M. Shtivelband, 2013, Breast.

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

P. Jänne, K. O'Byrne, T. Mok, 2014, The Lancet. Oncology.

A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo.

A. Heimberger, D. Lev, M. Bar‐eli, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.

Anand A. Dalal, G. Hortobagyi, B. Ramaswamy, 2019, Clinical breast cancer.

Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy.

L. Cranmer, P. Chalasani, M. Shtivelband, 2009, Clinical advances in hematology & oncology : H&O.

UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY

S. Kambhampati, J. Burke, I. Flinn, 2017 .

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.

J. Burke, K. Kolibaba, I. Flinn, 2017 .

Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.

A. Heimberger, M. Bar‐eli, A. Onn, 2004, The Journal of investigative dermatology.

Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab

D. Richards, R. Lyons, J. Sharman, 2021, Leukemia & lymphoma.

Purification and characterization of a cyclooxygenase‐2 and angiogenesis suppressing factor produced by human fibroblasts

D. Gilroy, Ying-hua Zhu, Kenneth K. Wu, 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).

M. Socinski, A. Sandler, M. Reck, 2018 .

Aspirin and salicylate inhibit colon cancer medium‐ and VEGF‐induced endothelial tube formation: correlation with suppression of cyclooxygenase‐2 expression

H. Juneja, M. Shtivelband, K. Wu, 2003, Journal of thrombosis and haemostasis : JTH.

Abstract P6-11-08: A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer

M. Campone, A. Urruticoechea, J. Beck, 2012 .

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC.

M. Socinski, D. Moro-Sibilot, C. Barone, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

V. Devanarayan, K. Pittman, T. Owonikoko, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

P. Neven, M. Piccart, G. Hortobagyi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

122TiP Phase III study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG 3515)

J. Rigas, S. Badiyan, H. Nasrallah, 2022, Annals of Oncology.